Why the study?
Reconsidering antithrombotic therapy in cancer patients nearing the end of life is complex, and patient experiences, values, and perspectives remain largely unexplored.
Design
Qualitative study using semi-structured interviews and Framework Analysis
Authors
Loading...
Patient perspectives on ATT near end-of-life inform DST development; leaves open need for prospective validation before practice change.
Patients with advanced cancer are hesitant to discontinue antithrombotic therapy but trust clinicians to lead decision-making, highlighting the need for shared decision-making tools.
Baddeley et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: